Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 15/064,158, filed Mar 8, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,377,245 | Method of Delivering a Therapeutic Agent to a Solid Tumor for Treatment In force · High confidence | Trisalus Life Sciences, Inc. | In force | High confidence | ||
| US 11,090,460 | Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment In force · High confidence | Trisalus Life Sciences, Inc. | In force | High confidence | ||
| US 12,433,597 | Atraumatic Occlusive System with Compartment for Measurement of Vascular Pressure Change In force · High confidence | Trisalus Life Sciences, Inc. | In force | High confidence | ||
| US 12,661,486 | Systems and Methods to Sense Characteristics of a Therapeutic Agent in Vivo In force · Medium confidence | Trisalus Life Sciences, Inc. | In force | Medium confidence | ||
| US 12,667,693 | Therapeutic Treatment Device with Braided Microvalve Occluder In force · High confidence | Trisalus Life Sciences, Inc. | In force | High confidence | ||
| US 8,372,413 | Immunomodulatory Polynucleotides and Methods of Using the Same Term ended · USPTO later recorded non-payment Mar 17, 2025 Term ended Feb 2, 2023 · Medium confidence | Trisalus Life Sciences, Inc. | Term ended USPTO later recorded non-payment Mar 17, 2025 | Term ended Feb 2, 2023 | Medium confidence | |
| US 8,158,768 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Trisalus Life Sciences, Inc. | Term ended | Term ended Dec 18, 2023 | Medium confidence | |
| US 8,871,732 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Trisalus Life Sciences, Inc. | Term ended | Term ended Dec 18, 2023 | Medium confidence | |
| US 9,422,564 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended · USPTO later recorded non-payment Sep 30, 2024 Term ended Dec 18, 2023 · Medium confidence | Trisalus Life Sciences, Inc. | Term ended USPTO later recorded non-payment Sep 30, 2024 | Term ended Dec 18, 2023 | Medium confidence | |
| US 10,196,643 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Trisalus Life Sciences, Inc. | Term ended | Term ended Dec 18, 2023 | Medium confidence | |
| 10 more patents in this group · Pro | ||||||
10 of 20 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 20, including 6 expired.
5 of these are in force and held by Trisalus Life Sciences, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.